GlassScriptPhysician profile
Farhan M Khan
NPI 1811195779
$3,184.90
in general payments reported to CMS, 2019-2025
21 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $48.38 · 2021: $577 · 2022: $408 · 2023: $1,045 · 2024: $769 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $636.92 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $570.91 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $415.19 | 2023-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $236.37 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $235.11 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $149.99 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $147.57 | 2021-2024 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.68 | 2024 | Caplyta |
| Tris Pharma INC | $120.94 | 2022-2025 | Onyda Xr |
| Axsome Therapeutics, INC. | $105.96 | 2024-2025 | Auvelity |
| Neos Therapeutics, LP | $105.07 | 2020-2024 | Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $82.13 | 2024-2025 | Relexxii |
| Neurocrine Biosciences, INC. | $54.85 | 2024 | Ingrezza |
| Lundbeck LLC | $41.77 | 2022-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $36.40 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $33.33 | 2023 | Xelstrym, Secuado |
| Shield Therapeutics INC | $18.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.71 | 2023 | Quviviq |
| Neuronetics, INC. | $18.64 | 2023 | Neurostar Tms Therapy System |
| Almatica Pharma LLC | $17.07 | 2025 | Loreev Xr |
| Livanova USA, INC. | $15.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.